Concepts (129)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 8 | 2025 | 411 | 2.220 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 2 | 2022 | 9 | 1.530 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2022 | 39 | 1.500 |
Why?
|
| Nevus, Pigmented | 4 | 2024 | 19 | 1.200 |
Why?
|
| Skin Diseases | 3 | 2025 | 83 | 1.130 |
Why?
|
| Psoriasis | 2 | 2025 | 57 | 1.060 |
Why?
|
| Ustekinumab | 1 | 2025 | 4 | 0.950 |
Why?
|
| Pulmonary Eosinophilia | 1 | 2025 | 10 | 0.950 |
Why?
|
| Bronchitis | 1 | 2025 | 30 | 0.940 |
Why?
|
| Dermatologic Agents | 1 | 2025 | 22 | 0.940 |
Why?
|
| Eosinophilia | 1 | 2025 | 37 | 0.930 |
Why?
|
| p120 GTPase Activating Protein | 1 | 2019 | 1 | 0.640 |
Why?
|
| Port-Wine Stain | 1 | 2019 | 10 | 0.640 |
Why?
|
| Capillaries | 1 | 2019 | 30 | 0.640 |
Why?
|
| Cerebral Palsy | 1 | 2019 | 18 | 0.630 |
Why?
|
| Arteriovenous Malformations | 1 | 2019 | 44 | 0.620 |
Why?
|
| Arteriovenous Fistula | 1 | 2019 | 41 | 0.620 |
Why?
|
| Spinal Cord Diseases | 1 | 2019 | 41 | 0.610 |
Why?
|
| Deep Sedation | 1 | 2018 | 4 | 0.600 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2018 | 6 | 0.600 |
Why?
|
| Surgical Stomas | 1 | 2018 | 9 | 0.600 |
Why?
|
| Nervous System Malformations | 1 | 2018 | 13 | 0.600 |
Why?
|
| Gynecological Examination | 1 | 2017 | 6 | 0.550 |
Why?
|
| Vaccination | 1 | 2020 | 364 | 0.530 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2018 | 102 | 0.530 |
Why?
|
| Hospitals | 1 | 2020 | 394 | 0.520 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 377 | 0.510 |
Why?
|
| Infant | 8 | 2025 | 1654 | 0.510 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2024 | 2188 | 0.500 |
Why?
|
| Parents | 1 | 2020 | 393 | 0.480 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 601 | 0.460 |
Why?
|
| Dermatology | 3 | 2025 | 75 | 0.430 |
Why?
|
| Nevus | 2 | 2025 | 22 | 0.420 |
Why?
|
| Melanosis | 2 | 2023 | 10 | 0.390 |
Why?
|
| Clinical Competence | 1 | 2017 | 730 | 0.380 |
Why?
|
| Child | 7 | 2025 | 4534 | 0.340 |
Why?
|
| Humans | 23 | 2025 | 63607 | 0.320 |
Why?
|
| Infant, Newborn | 4 | 2024 | 1362 | 0.300 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2022 | 641 | 0.290 |
Why?
|
| Male | 15 | 2025 | 29989 | 0.280 |
Why?
|
| Lymphatic Abnormalities | 1 | 2025 | 5 | 0.230 |
Why?
|
| Cryotherapy | 1 | 2025 | 16 | 0.230 |
Why?
|
| Lasers, Solid-State | 1 | 2025 | 18 | 0.230 |
Why?
|
| Hamartoma | 1 | 2025 | 12 | 0.230 |
Why?
|
| Radiation Exposure | 1 | 2025 | 23 | 0.230 |
Why?
|
| Laser Therapy | 1 | 2025 | 42 | 0.230 |
Why?
|
| Hair Follicle | 1 | 2025 | 34 | 0.220 |
Why?
|
| Retrospective Studies | 6 | 2023 | 6691 | 0.220 |
Why?
|
| Radiation Dosage | 1 | 2025 | 133 | 0.210 |
Why?
|
| Female | 10 | 2025 | 33001 | 0.210 |
Why?
|
| Nevus, Epithelioid and Spindle Cell | 1 | 2023 | 4 | 0.210 |
Why?
|
| Neurocutaneous Syndromes | 1 | 2023 | 9 | 0.200 |
Why?
|
| Nails, Malformed | 1 | 2023 | 6 | 0.200 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2025 | 237 | 0.200 |
Why?
|
| Radiography | 1 | 2025 | 551 | 0.200 |
Why?
|
| Pigmentation Disorders | 1 | 2023 | 9 | 0.200 |
Why?
|
| Castleman Disease | 1 | 2022 | 4 | 0.200 |
Why?
|
| Mucositis | 1 | 2022 | 8 | 0.200 |
Why?
|
| Pemphigus | 1 | 2022 | 14 | 0.190 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2022 | 10 | 0.190 |
Why?
|
| Neurofibromatosis 1 | 1 | 2023 | 31 | 0.190 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2022 | 23 | 0.190 |
Why?
|
| Nail Diseases | 1 | 2023 | 49 | 0.190 |
Why?
|
| Pediatrics | 1 | 2025 | 257 | 0.190 |
Why?
|
| Glucocorticoids | 1 | 2022 | 189 | 0.170 |
Why?
|
| Autoimmune Diseases | 1 | 2022 | 229 | 0.170 |
Why?
|
| Acitretin | 1 | 2020 | 1 | 0.170 |
Why?
|
| Keratolytic Agents | 1 | 2020 | 2 | 0.170 |
Why?
|
| Ichthyosis | 1 | 2020 | 8 | 0.160 |
Why?
|
| Incretins | 1 | 2020 | 8 | 0.160 |
Why?
|
| Peptide YY | 1 | 2020 | 3 | 0.160 |
Why?
|
| Glucagon | 1 | 2020 | 33 | 0.160 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2020 | 25 | 0.160 |
Why?
|
| Melanoma | 1 | 2023 | 331 | 0.160 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2020 | 85 | 0.160 |
Why?
|
| Luteinizing Hormone | 1 | 2020 | 100 | 0.160 |
Why?
|
| Thoracic Vertebrae | 1 | 2019 | 35 | 0.160 |
Why?
|
| Treatment Outcome | 2 | 2022 | 5705 | 0.160 |
Why?
|
| Reproduction | 1 | 2020 | 92 | 0.160 |
Why?
|
| Immunization | 1 | 2020 | 133 | 0.160 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2020 | 88 | 0.160 |
Why?
|
| Testosterone | 1 | 2020 | 121 | 0.150 |
Why?
|
| Skin Care | 1 | 2018 | 7 | 0.150 |
Why?
|
| Reproductive Health | 1 | 2019 | 25 | 0.150 |
Why?
|
| Adolescent | 4 | 2022 | 6257 | 0.150 |
Why?
|
| Fertility | 1 | 2019 | 83 | 0.150 |
Why?
|
| Rheumatic Diseases | 1 | 2019 | 40 | 0.150 |
Why?
|
| Vaccines | 1 | 2020 | 98 | 0.140 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 144 | 0.140 |
Why?
|
| Child, Preschool | 2 | 2020 | 1999 | 0.140 |
Why?
|
| Biomarkers | 2 | 2020 | 1410 | 0.140 |
Why?
|
| Models, Anatomic | 1 | 2017 | 64 | 0.130 |
Why?
|
| Inpatients | 1 | 2020 | 305 | 0.130 |
Why?
|
| Gynecology | 1 | 2017 | 55 | 0.130 |
Why?
|
| Disease Management | 1 | 2018 | 233 | 0.130 |
Why?
|
| Video Recording | 1 | 2017 | 136 | 0.130 |
Why?
|
| Task Performance and Analysis | 1 | 2017 | 129 | 0.130 |
Why?
|
| Feasibility Studies | 1 | 2018 | 571 | 0.130 |
Why?
|
| Obstetrics | 1 | 2017 | 86 | 0.120 |
Why?
|
| Contrast Media | 1 | 2018 | 426 | 0.120 |
Why?
|
| Health Personnel | 1 | 2020 | 370 | 0.120 |
Why?
|
| Educational Measurement | 1 | 2017 | 219 | 0.120 |
Why?
|
| Health Promotion | 1 | 2020 | 500 | 0.120 |
Why?
|
| Interviews as Topic | 1 | 2017 | 524 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 764 | 0.110 |
Why?
|
| Age Factors | 1 | 2018 | 1566 | 0.110 |
Why?
|
| Adult | 5 | 2022 | 16894 | 0.110 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 2588 | 0.100 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 2699 | 0.090 |
Why?
|
| Postoperative Complications | 1 | 2018 | 1314 | 0.090 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 2464 | 0.080 |
Why?
|
| Single-Blind Method | 2 | 2020 | 144 | 0.080 |
Why?
|
| Cross-Over Studies | 2 | 2020 | 163 | 0.080 |
Why?
|
| Middle Aged | 2 | 2022 | 17701 | 0.070 |
Why?
|
| Young Adult | 3 | 2022 | 4711 | 0.060 |
Why?
|
| Pain, Procedural | 1 | 2025 | 3 | 0.060 |
Why?
|
| Prognosis | 2 | 2020 | 1748 | 0.060 |
Why?
|
| Atrophy | 1 | 2025 | 83 | 0.060 |
Why?
|
| Cafe-au-Lait Spots | 1 | 2023 | 7 | 0.050 |
Why?
|
| Mosaicism | 1 | 2023 | 30 | 0.050 |
Why?
|
| Melanins | 1 | 2022 | 24 | 0.050 |
Why?
|
| Healthy Volunteers | 1 | 2020 | 73 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2020 | 121 | 0.040 |
Why?
|
| Rheumatology | 1 | 2019 | 67 | 0.040 |
Why?
|
| Counseling | 1 | 2019 | 366 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1258 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 725 | 0.030 |
Why?
|
| Brain | 1 | 2022 | 1556 | 0.030 |
Why?
|
| Aged | 1 | 2019 | 14511 | 0.010 |
Why?
|